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DEAR EDITOR, In a recently published research letter, Burney
et al. demonstrated that isotretinoin (13-cis-retinoic acid,
13CRA) induced acnegenic changes in cultured human SEB-1
sebocytes.1 However, Melnik et al.2 suggested that the
observed changes may largely be influenced by the Simian
virus 40 (SV40) immortalization of the used cell line, which
may inhibit the p53 pathway and, together with 13CRA, lead
to changes such as downregulation of the forkhead box O
(FOXO) pathway. In contrast, they found that the FOXO path-
way was upregulated in samples from patients receiving
13CRA treatment for 6 weeks.2 Importantly, the prominent
differences, that 13CRA treatment arrests the cell cycle and
induces apoptosis in SEB-1 sebocytes while in SZ95 sebocytes
(a cell line also immortalized with the SV-40 large T antigen)
13CRA treatment does not affect programmed cell death,3,4
suggest that SV-40 immortalization is not a fate-determining
factor in these cell lines.
Looking beyond these limitations, which arise from match-
ing findings from a cell line with data from in vivo samples
obtained at a given time point, the most challenging question
regarding the effects of 13CRA is whether it is, indeed, the
molecule responsible for the in vivo and in vitro observed
changes. Besides having a weak binding affinity to its target
receptors, RARs (retinoic acid receptors) and RXRs (retinoid X
receptors), and a poor potential for direct transcriptional acti-
vation, 13CRA rapidly isomerizes to all-trans RA (ATRA) and
other RA isomers. Therefore, it is generally assumed that
13CRA exerts its biological effect by serving as a precursor for
ATRA and/or 9-cis-retinoic acid isomers, which can efficiently
activate RARs and RXRs or even both in combination. This is
further supported by the findings that 13CRA treatment results
in low intracellular 13CRA and high intracellular ATRA levels
in sebocytes.5
To assess the direct changes that 13CRA could exert in
sebocytes we treated SZ95 sebocytes6 with 13CRA for 6 h and
24 h, and collected samples for RNA-Seq analysis to reveal
genome-wide changes. While the 6-h time point – when con-
version of 13CRA to its metabolites is still limited – allowed
us to identify direct changes, the 24-h time point, when
13CRA is already converted,5 revealed the long-term changes
at the level of gene expression. Our RNA-Seq analysis con-
firmed that of the 361 genes showing significantly changed
expression levels at 6 h, only 45 remained significantly
upregulated at 24 h in response to 13CRA (Fig. 1a). Further,
the majority of these 45 genes had a decreased fold change at
24 h when compared with the values detected in the 6-h sam-
ples (full data available on request). These findings confirm
that the effects of 13CRA are rather temporary on gene
expression level in sebocytes.
To link the detected changes to possible cellular functions,
we clustered the differentially expressed genes at 6 h using
the PANTHER Classification System (pantherdb.org). The clus-
tering revealed that gene expression changes were mostly
related to an altered growth factor and to other differentiation
pathways such as Wnt (the key pathway in sebocyte differen-
tiation) but not to lipid metabolism. When clustering genes
from the 6-h time point that remained significantly altered at
24 h, results confirmed a central role for the phosphatidyli-
nositol 4,5-bisphosphate 3-kinase catalytic subunit gamma
gene (PIK3CG, also known as PI3K-gamma) and its related
pathways (p53, VEGF, Ras, hypoxia, IGF, EGF, FGF, PDGF,
apoptosis and angiogenesis signalling); which was shown to
be upregulated also in the non-SV-40 immortalized U937
myeloid cells on ATRA treatment.7 Moreover, 13CRA activated
the PIK3CG/Akt/FOXO pathway not only in SZ95 sebocytes
in vitro but also in sebaceous glands of 13CRA-treated patients
with acne.8 Importantly, when comparing the lists of those
genes regulated by 13CRA with a list of the immediately
responding target genes of ATRA (3 h after ATRA treatment)
in SZ95 sebocytes, we found a limited overlap (Fig. 1b). Such
a weak signature of a possible ATRA-related effect in the
13CRA-induced gene expression profile and the related func-
tional clusters (Fig. 1c) suggests that mechanisms involving
alternative 13CRA metabolites may also have to be taken into
account to explain the therapeutic effects of 13CRA treatment.
In conclusion, our RNA-Seq analysis supports the hypothesis
that 13CRA is, rather than the direct effective agent, a precur-
sor for alternative bioactive retinoids. To develop novel reti-
noids with better efficacy and fewer adverse effects, it is
essential to understand in more detail the overall molecular
mechanisms of RA metabolism, such as dehydrogenation and
isomerization, which are distinct from the conversion of
13CRA to ATRA (Fig. 1d).
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Fig 1. (a, b) Venn diagrams showing the numbers of significantly regulated genes from the RNA-Seq analysis of SZ95 sebocytes when treated
with: 1 lmol L1 13-cis-retinoic acid (13CRA) for 6 h and 24 h (a), and with 1 lmol L1 13CRA for 6 h and 24 h and 1 lmol L1 all-trans RA
(ATRA) for 3 h (b), compared with untreated sebocytes. (c) Pathway analysis of the differentially expressed genes. In black are the clusters and
related genes that were differentially expressed in sebocytes 6 h after 13CRA treatment, while in red are those that were differentially expressed in
all of the examined conditions. (d) Metabolic pathways starting from 13CRA to known RA isomers and to dihydroretinoids, which may confer
additional, still unknown, therapeutic effects. ATDHRA, all-trans-13,14-dihydroretinoic acid; DCRA, di-cis-RA; 9CDHRA, 9-cis-13,14-dihydroretinoic
acid; 5HT, 5-hydroxytryptamine; EGF, epidermal growth factor; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; TGF,
transforming growth factor; VEGF, vascular endothelial growth factor.
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